Extracorporeal Photopheresis in Graft-versus-Host Disease
Transfusion Medicine and Hemotherapy2020Vol. 47(3), pp. 214–225
Citations Over TimeTop 10% of 2020 papers
Abstract
ECP is a well-established second-line therapy for cGvHD. Its role in the treatment of aGvHD is less clear but also points towards an effective second-line therapy option. In the future ECP could play a role in the prevention of GvHD. More experimental and randomized controlled trials are needed to define the best patient selection criteria, settings, and therapy regimens for GvHD.
Related Papers
- → Clinical Results of Extracorporeal Photopheresis(2012)16 cited
- → Extracorporeal Photopheresis in Dermatology(2009)5 cited
- → MINI-PHOTOPHERESIS – A NON-LEUKAPHERESIS BASED EXTRACORPOREAL PHOTOPHERESIS: CLINICAL EXPERIENCE(2021)2 cited
- → Extracorporeal photopheresis: Is one ounce of blood enough? Case reports(2023)1 cited
- → Extracorporeal photopheresis: is one ounce of blood enough? Cases report(2023)